-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CLEVELAND – According to a new finding from the Cleveland Clinic's Lerner Institute, the HSD3B1 gene may provide clues
Based on the findings published in the JNCI Cancer Spectrum, the researchers found that a certain HSD3B1 genotype is more common
The result is the latest step in unlocking the role that HSD3B1 genotype plays in hormone-driven cancer, after previous studies have revealed its association
Nima Sharifi, MD, senior author of the paper and director of the Research Center for Genitourinary Malignancies at the Lerner Institute, said HSD3B1 researchers are laying the groundwork for future treatment and prevention of cancer subtypes with lower survival rates
Although endometrial cancer is one of the most common cancers in women, there are currently no tests or tests to screen for endometrial cancer
"We haven't changed the criteria for results over the last 30 years," Dr.
HSD3B1 is a gene
Dr.
Previous studies have determined how the HSD3B1 gene works, and how it relates to hormone-associated cancers, starting
Dr.
The purpose of castration is to stop the production
Dr.
Recent studies have investigated a potential link between the genotype of HSD3B1 and subtypes of postmenopausal breast and endometrial cancer in which cancer grows
Previous studies have linked
In endometrial cancer, the serous subtype ER is less expressed and the prognosis is poor
Lead author Dr.
Ongoing HSD3B1 collaborations include further research into the relationship of HSD3B1 to breast and endometrial cancers, as well as studies of how HSD3B1 is associated
with radiotherapy responses.
A clinical trial of prostate cancer at the Cleveland Clinic will test how people with a specific HSD3B1 genotype respond
to treatment.
The authors note that black women are more likely to inherit the HSD3B1 gene that restricts adrenal secretion, and that certain breast and endometrial cancer subtypes have worse outcomes, both of which are more common
in black women.
A study released in May by the National Cancer Institute showed that black women were twice as likely to die from uterine cancer as
other ethnic groups.
"Eliminating this difference in outcomes and trying to understand the genetic basis will be critical
to reducing (or eliminating) existing differences," Vargas said.
essay
Association between adrenal-restrictive HSD3B1 inheritance and hormone independent subtypes of endometrial and breast cancer